Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (July 2021)
54 slides from Corbus Pharmaceuticals's investor presentation, Jul 22, 2021
Slide 1: Corbus Pharmaceuticals
> PHARMACEUTICALS ———_
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Co
Slide 3: Expanding Our Therapeutic Focus
Expanding Our Therapeutic Focus [/__—_—_____ CONTINUED FOCUS —————_+} seeeee EXPANDED FOCUS - - --- - » ) Expertise across all phases of | drug development \ Track record of executing | complex global studies on ) / time and on budget I | Funded through Q1 2024
Slide 4: A Diverse Pipeline with Multiple Shots on Goal
A Diverse Pipeline with Multiple Shots on Goal »; Compound | Therapeutic Areas / Indications | Preclinical Phase 1 Phase2 —-Phase3 Dermatomyositis* | | ay Lenabasum . ee uns ss CB1 Inverse Metaboli rt i Agonists ; CB2 Agonists Solid Tumors LD Anti-avB8 mAb Solid Tumors |) Anti-avB6/avB8 mAb Fibrosis
Slide 5: Program 1: Targeting the Endocannabinoid System
PROGRAM 1: TARGETING THE ENDOCANNABINOID SYSTEM
Slide 6: Endocannabinoid System GPCRs
Endocannabinoid System 2 GPCRs: CB1 and CB2 2 endogenous agonists: anandamide & 2-AG Metabolicenzymes FAAH and MAGL Haspula, et al. Cannabinoid Receptors: AnUpdate on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and inflammatory Diseases, In
Slide 7: Lenabasum: A Late-Stage CB2 Agonist for Autoimmune Diseases
LENABASUM: A LATE-STAGE CB2 AGONIST FOR AUTOIMMUNE DISEASES
Slide 8: Lenabasum: CB2 Agonist in Late-Stage Development
Lenabasum: CB2 Agonist in Late-Stage Development PURPOSE Inflammatory and fibrotic diseases INNOVATION ¢ First-in-class Targets activatedimmune cells © Non-immunosuppressive * Add-onto current therapies MOA * Activates resolution of inflammation « Reduces levels of inflammatory mediators « Inhibits
Slide 9: Key Lenabasum Phase 3 and Studies
Key Lenabasum Phase 2 and 3 Studies Target (Program) Number Dosed +Primary efficacy endpoint (Total Improvement Score) not met Dermatomyositis 3 175 + Additional data analyses being completed and preparing for discussions with FDA SLE 2 102 + Ongoing, topline data expected second half of 2021 +Prima
Slide 10: Dermatomyositis at a Glance
Dermatomyositis at a Gle DERMATOMYOSITIS der-mat-o-my-o'si-tis Chronic, rare, inflammatory, clinically heterogenous autoimmune diseases 10% Dermatomyositis (DM) Subtypes 20% = Classic DM (Muscle weakness and skin involvement) Amyopathic/hypomyopathic DM (no or little muscle weakness but skin involve
Slide 11: Dermatomyositis Mortality and Patient Population
30% MORTALITY gE: - 80,000 People in North America, Europe and Japan'2 CONDITION MAY BE ; Typically treated with FATAL IN ADULTS 6 immunosuppressants : and immunomodulating agents with due to severe muscle weakness, © © © © H vari able effectiveness malnutrition, pneumonia and lung failure? wennnnnn
Slide 12: Phase 3 DETERMINE Study Protocol
Phase 3 DETERMINE Study Protocol Double-blind, Randomized, Placebo-controlled study Trial in adults with active classic dermatomyositis or amyopathic/hypomyopathic dermatomyositis — PRIMARY ENDPOINT .-------- . — KEY SECONDARY ENDPOINTS -------- , ACR & EULAR 2016 Total Improvement Score (TIS) in Ad
Slide 13: Phase 3 Study did not Meet Primary Endpoint of TIS at Week 28
Phase 3 Study did not Meet Primary Endpoint of Total Improvement Score (TIS) at Week 28 Lenabasum was Associated with Higher TIS Compared to Placebo at all Timepoints N=35, 39 45 40.6 N=65, 66 *p = 0.1965 N=66,67 28.3 * Nominal p = 0.0795, lenabasum 20 mg a 348 twice daily (BID) group versus control
Slide 14: Highest Improvement in TIS Seen in Subjects with Muscle Weakness
Highest Improvement in TIS Seen in Lenabasum-Treated Subjects with Muscle Weakness (MMT-8 < 142] x 4 N=24, 26 5 44.8 N= 26,27 45 N=41, 43 40 *p=0.1959 321 35 39.3 * Nominal p = 0.0302, lenabasum 20 mg twice daily (BID) group versus control, overall, visits Weeks 4-52, MMRM TIS, Mean (SEM) 20 5 10 5
Slide 15: Greater Improvement in CDASI Activity Scores vs. Placebo
Greater Improvement in CDAS! Activity Scores Seen in Lenabasum Treated Subjects vs. Placebo »; ACDASI activity score, mean (SEM) -14 ~® Control N=35,39 —m@> Lenabasum 20 mg BID 0 4 8 2 16 2 24 2 32 36 40 44 48 §2 Week Fixed effects in MMRM were baseline CASI, treatment, corticosteroid use, visit, ba
Slide 16: Phase 2 Dermatomyositis Biomarkers: Reduced CD4 and CB2 Expression
Phase 2 Dermatomyositis Study Biomarkers: Lenabasum Treatment Reduced CD4 and CB2 Expression in Lesional Skin from Dermatomyositis Subjects Lenabasum treatment was associated with reduction in Lenabasum treatment was associated with reduction in CD4+ T cell infiltration in skin biopsies in DM CB2 in
Slide 17: Phase 2 Dermatomyositis Biomarkers: Reduced Interferon-B and IFNy
Phase 2 Dermatomyositis Study Biomarkers: Lenabasum Treatment Reduced Interferon-B and IFNy Expression in Lesional Skin from Dermatomyositis Subjects Lenabasum treatment was associated with reduction in Lenabasum treatment was associated with reduction in interferon-B in skin biopsies in DM interfer
Slide 18: Competitive Landscape
Competitive Landscape Treatment Target & Delivery Company Subjects Endpoint CB2 agonist 3 Lenabisum (ora) CORBUS (Primary endpoint not met 2021) ia Tse atiee sy 0, Approved 2021 Number of patients who had an increase of =20 points on the octaganr 10% Mg (Pfized (Primary endpoint met) iu TISat 16 wee
Slide 19: SLE: Topline Phase 2 Study Results Expected 2H 2021
Systemic Lupus Erythematosus (SLE): Topline Phase 2 Study Results Expected 2H 2021 x PRIMARY ENDPOINT: « Mean 7-day average maximum daily pain numerical rating score (NRS) at 12 weeks, n= 101 STUDY FUNDED AND MANAGED BY THE AUTOIMMUNITY CENTERS OF EXCELLENCE AT THE KEY SECONDARY ENDPOINTS: NATIONAL
Slide 20: 2nd Generation CB1 Inverse Agonists for Metabolic and Fibrotic Diseases
2ND GENERATION CB1 INVERSE AGONISTS FOR METABOLIC AND FIBROTIC DISEASES
Slide 21: _ | -
_ | -
Slide 22: CB1 Activation Contributes to "Diabesity"
CB1 Activation Contributes to “Diabesity” CB1 ACTIVATION INCREASES: + Appetite + Foodintake + Fat production and storage + Insulinresistance + Inflammation + Fibrosis CB1 ACTIVATION DECREASES: + Insulinsecretion + Fat oxidation + Energy expenditure ‘veba, etal. Targeting tho endocannabinoid systom i
Slide 23: CB1 is a Validated Target in Metabolic Diseases
CB1is a Validated Target in Metabolic Diseases x SEVERAL FIRST GENERATION CB1 INVERSE AGONISTS ADVANCED TO LATE-STAGE CLINICAL DEVELOPMENT = ii MPLIAY i SANOFl eg } ae “] _ SECOND GENERATION OF Fn | aac _ CBIINVERSE AGONISTS eS Phize Approved in EU and launched in 2006 for treatment AIM TO MAINTAIN
Slide 24: CB1 Inverse Agonist Program
CB1 Inverse Agonist Program PURPOSE * Obesity, diabetes/diabetic nephropathy, NASH Intestine INNOVATION Second generation small molecule with limited brain levels to increase safety Pancreas « Potential to augment effects of GLP-1R agonists in diabetes and obesity © Potential to preserve renal funct
Slide 25: DIO Model: CRB-556 Induces Weight Loss in Obese Mice
DIO Model: CRB-556 Induces Weight Loss in Obese Mice + CBlinverse agonist CRB-556 induced dose-dependent weight loss in mice with diet-induced obesity 7 4M CRB-556 5 mg/kg BID + Effect similar to rimonabant ___ @ Rimonabant 10 mg/kg QD 4 =CRB-556 10 mg/kg BID Time (Days) Chow diet High fat diet Mice
Slide 26: DIO Model: CRB-556 Improves Glucose Tolerance and Insulin Sensitivity
DIO Model: CRB-556 Improves Glucose Tolerance and Insulin Sensitivity in Obese Mice CRB-556 improved glucose tolerance and insulin sensitivity in mice with diet-induced obesity, similar to rimonabant Vehicle BID -@ Rimonabant 10 mg/kg QD -s CRB-556 5 mg/kg BID -™ CRB-556 10 mg/kg BID 350 oGTT 100: I
Slide 27: CRB-4001 Augments Weight Loss Provided by Semaglutide
CRB-4001 Augments Weight Loss Provided by Semaglutide in Obese Mice -@ Vehicle ~® Semaglutide -@ CRB-4001 ~® Semaglutide + CRB-4001 02 4 6 8 Time (days) 10 12 14 *P< 0.05; *** P< 0.001, comparing semaglutide (1 nmol /kg shown) + CRB-4001 (1 mg/kg shown) Versus monotherapies (N = 8 mice per group) Gr
Slide 28: CRB-4001 Improves Renal Structure Function in Diabetic Nephropathy
CRB-4001 Improves Renal Structure Function in a Model of Diabetic Nephropathy < 200. 30, F s000) : £1500 F100 S z ae a i 8s) , if 7 + gx sooo ME Esco Rie Bowe Pal = 5 35 u EF ol | Im | Miszeve $ # 3 10 2000 500: ae a % 20 [ siz--cre-4001 0. 0. oo 0. * 0. #P < 0.05 relative to the corresponding strep
Slide 29: Corbus CB1 Inverse Agonists Have Low Brain Drug Levels
Select Corbus CB1 Inverse Agonists Have Low Brain Drug Levels and Receptor Occupancy with Re CBi Receptor Coax AUC 24 Occupancy in Brain, Compound Brain: Plasma Brain: Plasma Chronic Dosing, Comment (Ratio, Range) (Ratio, Range) 10-20 mg/kg Rimonabant (Sanofi 090->1 - — Single P dose cRB-4001* 0.06-
Slide 30: New Drug Class: Cannabinoid Receptor Agonists for Solid Tumors
NEW DRUG CLASS: CANNABINOID RECEPTOR AGONISTS FOR SOLID TUMORS
Slide 31: CB2 Agonist Immuno-oncology Program
CB2 Agonist Immuno-oncology Program PURPOSE Solid tumors in combination with standard treatmentsincluding checkpoint inhibitors INNOVATION © First-in-class * Affects both tumor cells and immune system * Potential to augment effects of CPls MOA Inhibits cell cycle progression Inhibits cell proliferat
Slide 32: Corbus CB2 Agonists Reduce Cancer Cell Viability
Corbus CB2 Agonists Reduce Cancer Cell Viability by Promoting Apoptosis Inhibition of cancer cell viability, IC50 (uM) Compound CRB-199* . . . 31 54 40 5.4 >10 CRB-378* 8.0 ! I 36 84 40 10.4 138 *Ourent candidates under evabaionfor potential clnicaldevelopment s Ps & 8 s 8 20 | as Fold Induction (vs
Slide 33: CRB-378 Has Single Agent Activity in Breast Cancer Xenograft Model
CRB-378 Has Single Agent Activity in HCC1954 Her2+ Breast Cancer Xenograft Model x CRB- 378 REDUCES TUMOR VOLUME CRB- 378 IS CONCENTRATED IN THE TUMOR ‘600 -* Vehicle 4 CRB-378 5 mg/kg (tumor) 1400 -® CRB-378, 5 mg/kg BID t- CRB-378 10 mg/kg (tumor) £ -- CRB-378, 10 mg/kg BID _~ 1000 -@- CRB-378 5mg
Slide 34: Program 2: Targeting TGFB Activating Integrins
(y PROGRAM 2: TARGETING TGFB ACTIVATING INTEGRINS
Slide 35: Immune Evasion is Mediated by TGFB in Late-Stage Tumors
3° Immune Evasion is Mediated by TGF in Late-Stage Tumors Pro-inflammation 17 ~~ 6. 2» = y= Pro-inflammation dig Cancer Cells Stromal Cells Lime TME Human NSCLC \ 4 moscs _Diferentation [ Immune/ CD4* , Can tumor Supp SHEE = Jct —— OOwrrz py teen 6 ; 100: i v ©) ss bd ogo —~_) Cyukies Herd is B 50 T
Slide 36: Lower Survival in Patients with High TGFB Tumor Gene Signature
Lower Survival in Patients with High T6FB Tumor Gene Signature IN CONCORDANCE WITH LOW DEATH RISK Li “1 HIGH DEATH RISK Cr N=8,461 cancers, multiple cell types 1.0 ol, #* \ $s 3 4 Strong concordance between 2 TGF immune expression Ze signature score and overall =o) survival for each immune [4 subtyp
Slide 37: avB8 on Tumor Cells Activates TGFB
avB8 on Tumor Cells Activates T6FB DIFFUSIBLE ACTIVE TGFB. NON-DIFFUSIBLE ACTIVE TGFB integrin aps Be Untastened ae TOF-B1 stmigttciat mTGF-B1g activation * oe MHG-8 binding footprint GARPeco Lidnart. etal Structura/basisoflatent TOF61 ‘presentationandactivaton by GARPontuman ‘requotory Tels, Scienc
Slide 38: Drug Development of Inhibitors of TGFB-Activating Integrins
Drug Development of Inhibitors of TGFS-Activating Integrins ONCOLOGY PHASE (asetesen worcaTiOn) Phase 1 8 © Pfizer Solid tumors cael A D Preclinical avps @ Phase 2 avpe/I @ | ST PLIANT PFBPSC MORPHICZS Preclinical aps @ Preclinical api @ VENN Preclinical vps Preclinical apes | Phase 1 Res 9 E = a ap
Slide 39: CRB-601: Anti-avB8 mAb for Solid Tumors
CRB-601: Anti-owB8 m/ b for So PURPOSE Treatment of solid tumors, in combination with standard treatments including checkpoint inhibitors INNOVATION Anti-avB8mAb from Nishimura lab (UCSF) * Genealogy: mC6D4 > hC6D4 > CRB-601 * Potential to augment effects of CPls MOA e Binds with high affinity to bl
Slide 40: C6D4 Inhibits Activation of Diffusible and Non-Diffusible TGFB
C6D4 (Precursor mAb Of CRB-601) Inhibits Activation of Both Diffusible and Non-Diffusible TGFB > Inhibition of Activation of: Non-Diffusible T6FB Diffusible TOFB z g mA > Anti-B8 (CD64) a > Anti-68 (CD64) 2 i = Anti-TOF-B gy © Anti-TGF-B s “> TOF-BR2-fe gs > TOF-BR2-fe a) _ = Anti-T6F-BR2 8 * Anti-T
Slide 41: C6D4 Augments Activity of Anti-PD-1 mAb
C6D4 (Precursor mAb Of CRB-601) Augments Activity of Anti-PD-1 mAb MC38 Syngeneic Mouse Colon Cancer Model © 1000 eee fe 100 - de i fe ig bat 3 60 : £ © Isotypecontrol Abs 5 oe Fd © cena $ é —» anti-PD-ImAb $ 200 2 @ C6D4+anti-PD-1mAbs 0. : . stt tty tt hs 0 2 4 6 8 101214 16 18 2022 24 26 28 30 Day
Slide 42: Blocking Both TGFB and PD-1 Augments T Cell Infiltration
Blocking Both T6FB and PD-1 Augments T Cell Infiltration in Tumors * Majority of infiltrating cells are CD8+ T cells * Consistent with lessening immunosuppression Anti-TGFB Tumour periphery Tumour centre + CRB-601 + anti-PD-1 mAb have the potential to provide superior relief of immunosuppression Xe
Slide 43: CRB-601 Highly Effective at Inhibiting avB8-mediated TGFB Activation
CRB-601 is Highly Effective at Inhibiting avB8-mediated TGFB Activation In Vitro @ Antibody control N/A Anti-TGFB mAb 21.85 pg/ml © Precursor mAb of 0.55 ug/ml CRB-601 (C6D4) A CRB-601 0.05 pg/ml 50 TML cells = i= 2 r= _ £ & & s i= 2 =] iJ 2 =] oO Oo ia So uw e af 0 [Antibody (ug/ml)] (log10) Nishim
Slide 44: CRB-601 More Effective In Vitro than Equivalent Pfizer mAb
CRB-601 Appears to be Significantly More Effective In Vitro at Inhibiting TGFB than Equivalent Pfizer mAb »; 150 100 50 TFG-B Activation (% Inhibition) -50 Antibody [log10] A CRB-601 0.75 ug/ml @ ADWANI (Pfizer mAb) 57.7 ug/ml OVCARS cells Nishimura, S.L., Cormier, A., Ito, S., Lou, J., Marks, J.D.,
Slide 45: CRB-601 Single Agent Effect in Syngeneic Lung Cancer Model
CRB-601 Has Single Agent Effect in Syngeneic Lung Cancer Tumor Animal Model Syngeneic model: Lewis lung carcinoma Tumor Volume Tumor Weight #k a A a Tumor Volume (mm?) Tumor Weight (g) a: #3 mAb Dose Escalation Cohorts ° mAb Dose Escalation Cohorts 4 a @ ControlmAb@2mg/kg m= CRB-601@2 mg/kg e@ Contr
Slide 46: CRB-602: Anti-avB6/8 mAb for Fibrosis and Cancer
CRB-602: Anti-ccv36/8 mAb for Fibrosis and Cancer INCREASED EXPRESSION OF owv36 IN FIBROTIC AREAS IN LUNG OF 0 Dice SeCRi mn TASTE EEN OUT IDIOPATHIC PULMONARY FIBROSIS (IPF) SUBJECTS * av§é6 integrin also activates TGFB 1*PETimage_¢ _ 2™PET scan * avB6 is expressed in high levels on tumors of epith
Slide 47: Expected Clinical Milestones 2021-2022
Expected Clinical Milestones 2021-2022 ¥ PROGRAM MILESTONE PHASE 2 DATA PHASE 1 PHASE 1 PHASE 1 PHASE 1
Slide 48: Financial Profile: Common Shares Outstanding
| 2 A M Common Shares Outstanding (140.1M Fully Diluted)— — — - STON “ssttaanceasot 3 sz0zt FINANCIAL PROFILE: CRBP (NASDAQ)
Slide 49: A Team with a Proven Record of Execution
A Team with a Proven Record of Execution Yuval Cohen, PhD Chief Executive Officer, Director Executive leadership experience in inflammatory disease drug Barbara White, MD Chief Medical Officer and Head of Research Previous academician with industry, clinical \ development, and medical affairs experi
Slide 50: An Experienced and Engaged Board of Directors
An Experienced and Engaged Board of Directors Avery W. (Chip) Catlin Director More than 25 years of senior financial leadership experience in life science companies; Former CFO and Secretary of Celldex Therapeutics Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service i
Slide 51: Connecting Innovation to Purpose
Connecting Innovation to Purpose NASDAQ: CRBP - CorbusPharma.com - @CorbusPharma
Slide 52: RESOLVE-1 Phase 3 in Systemic Sclerosis
RESOLVE-1 Phase 3 in Systemic Sclerosis Largest ever study in diffuse cutaneous systemic sclerosis (n=365, 52-weeks, 76 global sites) First in a group of studies to allow patients to remain on background immunosuppressant therapy (IST) RESULTS Study did not meet primary endpoint KEY LEARNINGS Under-
Slide 53: Phase 3 Subjects Treated With Lenabasum Added to Established IST
PHASE 3 - Subjects Treated With Lenabasum 20 mg BID Added to Established IST (> 2 Year Duration) Had Stable FVC % Predicted POST-HOC ANALYSES Subjects treated with lenabasum 20 mg BID added to established immunosuppressant therapies (IST) had stable FVC % predicted over 1 year Nominal P = 0.039 . Qt
Slide 54: CRB-4001 Acts In a Variety of Key Metabolic Pathways
CRB-4001 Acts Ina Variety of Key Metabolic Pathways Hyperglycemia+ Byperetvestils CB,R antagonism/absence R a CBR Apical Basal Apical Basal membrane membrane membrane membrane inden, et al Moduationof Rent GLUT2by the Canabinit-! Receptor:Implications for the Treatment of Diabetic Nephropathy. Joura
Corbus Pharmaceuticals Holdings — Investor Presentation (July 2021) on 6ix